001     144469
005     20240229112626.0
020 _ _ |a 978-1-4939-9150-1 (print)
020 _ _ |a 978-1-4939-9151-8 (electronic)
024 7 _ |a 10.1007/978-1-4939-9151-8_17
|2 doi
024 7 _ |a pmid:30779044
|2 pmid
024 7 _ |a 1064-3745
|2 ISSN
024 7 _ |a 1940-6029
|2 ISSN
024 7 _ |a altmetric:70442529
|2 altmetric
037 _ _ |a DKFZ-2019-01920
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Tomska, Katarzyna
|0 P:(DE-He78)b19e65a29d89d299cf5a04670a7ff0ae
|b 0
|e First author
|u dkfz
245 _ _ |a Lymphoma and Leukemia Cell Vulnerabilities and Resistance Identified by Compound Library Screens.
260 _ _ |a [Heidelberg]
|c 2019
|b [Springer]
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Book
|0 PUB:(DE-HGF)3
|2 PUB:(DE-HGF)
|m book
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1565682141_16481
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Response to anticancer agents is often restricted to subsets of patients. The recognition of factors underlying this heterogeneity and the identification of biomarkers associated with response to drugs would greatly improve the efficacy of drug treatment. Platforms that can comprehensively map drug response in high-throughput ex vivo provide a unique tool to identify associated biomarkers and provide hypotheses for mechanisms underlying variable response. Such screens can be performed on cell lines and short-term cultures of primary cells to take advantage of the respective models' strength, which include, e.g., the ability to silence genes in cell lines and the 'indefinite' supply of primary cells where clonal selection can be avoided. Cohorts of such samples represent the natural diversity of cancers, including rarer mutations and combinatorial patterns of mutations.We here summarize a simple and scalable method for the measurement of viability after drug exposure based on ATP measurements as a surrogate for viability, which we use to measure and understand drug response in cell lines and primary cells.
536 _ _ |a 319H - Addenda (POF3-319H)
|0 G:(DE-HGF)POF3-319H
|c POF3-319H
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef Book Series, PubMed,
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
650 _ 7 |a Biomarkers, Pharmacological
|2 NLM Chemicals
700 1 _ |a Scheinost, Sebastian
|0 P:(DE-He78)648d23797edea029cdadba96810a9e8c
|b 1
|u dkfz
700 1 _ |a Zenz, Thorsten
|b 2
773 _ _ |a 10.1007/978-1-4939-9151-8_17
|0 PERI:(DE-600)2493551-7
|p 351-362
|t Methods in molecular biology
|v 1956
|y 2019
|x 1064-3745
909 C O |p VDB
|o oai:inrepo02.dkfz.de:144469
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)b19e65a29d89d299cf5a04670a7ff0ae
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)648d23797edea029cdadba96810a9e8c
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|2 G:(DE-HGF)POF3-300
|v Addenda
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
920 1 _ |0 I:(DE-He78)G250-20160331
|k G250
|l Molekulare Therapie in der Hämatologie und Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a book
980 _ _ |a I:(DE-He78)G250-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21